Genesis Global Group
PharmOptima
GD3

You will now be redirected to the GD3 website

PharmOptima is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Leadership

Madeline Farley, Ph.D.

Managing Director

Dr. Farley is the Managing Director of PharmOptima in Portage, Michigan. Dr. Farley has 15 years of experience in neuroscience research and preclinical contract work, emphasizing molecular biology, biochemistry, biophysics and disease modeling. Dr. Farley joined PharmOptima in 2021 as a Senior Scientist within the Biochemistry group. Apart from her role in Biochemistry, she has worked closely with the Vivarium to establish ocular disease models within the Ocular Center of Excellence. Before joining PharmOptima, Dr. Farley investigated injury signaling pathways underlying neurodegenerative disease and neuronal injury using transgenic mice and AAV-based gene delivery systems targeting neurons within the retina. Dr. Farley received her BS in Biochemistry, with a minor in Mathematics, from Centenary College of Louisiana. She earned her Ph.D. in Cellular and Molecular Neuroscience at The University of Texas Health Science Center in Houston, TX. She completed postdoctoral fellowships at both McGovern Medical School at UTHealth and Baylor College of Medicine. Dr. Farley has been a recipient of a vision sciences postdoctoral fellowship through the National Eye Institute and an individual NRSA predoctoral fellowship through the National Institute of Neurological Disorders and Stroke.